Spots Global Cancer Trial Database for azd4547
Every month we try and update this database with for azd4547 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | NCT01824901 | Recurrent Non-s... Squamous Cell L... | docetaxel AZD4547 | 25 Years - | Eastern Cooperative Oncology Group | |
| Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" | NCT02824133 | Recurrent IDHwt... Recurrent IDHwt... | AZD4547 | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients | NCT01202591 | FGFR Inhibition... ER+ Breast Canc... | AZD4547 Exemestane Placebo Fulvestrant | 18 Years - 99 Years | AstraZeneca | |
| A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | NCT05775874 | Urothelial Carc... | AZD4547 Tislelizumab | 25 Years - | Abbisko Therapeutics Co, Ltd | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" | NCT02824133 | Recurrent IDHwt... Recurrent IDHwt... | AZD4547 | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer | NCT01457846 | Gastro-oesophag... Gastric Cancer | AZD4547 paclitaxel | 25 Years - 130 Years | AstraZeneca | |
| Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | NCT01824901 | Recurrent Non-s... Squamous Cell L... | docetaxel AZD4547 | 25 Years - | Eastern Cooperative Oncology Group | |
| Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient | NCT01213160 | Cancer Advanced Solid ... | AZD4547 | 25 Years - 150 Years | AstraZeneca | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
